AN2 Therapeutics, Inc.ANTXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-26.21%
↓ 167% below average
Average (5y)
39.28%
Historical baseline
Range
High:180.88%
Low:-79.48%
Volatility
662.8%
High variability
| Period | Value |
|---|---|
| 2024 | -26.21% |
| 2023 | 85.93% |
| 2022 | 74.56% |
| 2021 | 180.88% |
| 2020 | -79.48% |
| 2019 | 0.00% |